Tolerability of N-chlorotaurine plus ammonium chloride in the rabbit and human eye – a phase 1 clinical study.

Drug-Resistant Infections

Pathogenics, Inc. is a biopharmaceutical company that acquires and develops new therapeutic drugs that have large sales potential (over $1 billion per year) and target unmet medical needs. We are currently developing a broad-spectrum anti-infective drug called
N-Chlorotaurine for topical and body cavity infections. This drug may safely treat multiple infections - many which have very large markets, and few, if any, satisfactory drug treatments.

Please click on the button below to view investor information and download our fact sheet.

Some of the information on this web site may contain projections or other forward-looking statements regarding future events or the future financial performance of Pathogenics Inc. We wish to caution you that these statements are only predictions and that actual events or results may differ materially from those predicted in these statements. We refer you to the documents that Pathogenics files from time to time with the Securities and Exchange Commision, specifically Pathogenics' most recent Form 10-KSB. This document contains and indentifies important factors that could cause our actual results to differ materially from those contained in our projections or forward looking statements. Copyright © 2008 by Pathogenics Inc. All rights reserved.